Search alternatives:
mm decrease » _ decrease (Expand Search), nn decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
mm decrease » _ decrease (Expand Search), nn decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
601
-
602
-
603
-
604
-
605
CNP decrease mitochondrial membrane potential and induce mitochondrial fragmentation in melanoma cells.
Published 2020“…<p>A, 300 μM CNP (4 h) significantly decreased mitochondrial membrane potential in A375 cells, but not in melanocytes, indicated by changes of TMRM dependent fluorescence in mitochondria. …”
-
606
-
607
-
608
Fiber length changes to ramp decreases in force applied at steady isometric force.
Published 2013“…<p>Ramp decreases in force from the level of steady Ca<sup>2+</sup>-activated isometric force to zero (complete in 0.15–0.3 s) were applied to one and the same muscle fiber at KCl concentrations of 0 mM (A), 50 mM (B), and 125 mM (C).…”
-
609
-
610
-
611
-
612
The apparent Ca<sup>2+</sup> affinity of release is decreased by hydrophobic mutations.
Published 2020“…The significant rightward shift in the curve (EC50, non overlapping confidence intervals) indicates a decrease in the apparent Ca<sup>2+</sup> affinity of neurotransmitter release.…”
-
613
-
614
-
615
-
616
-
617
-
618
-
619
-
620
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”